Efficacy of PET-CT in the prediction of metastatic adrenal masses that are detected on follow-up of the patients with prior nonadrenal malignancy: A nationwide multicenter case-control study.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
26 Aug 2022
26 Aug 2022
Historique:
entrez:
31
8
2022
pubmed:
1
9
2022
medline:
2
9
2022
Statut:
ppublish
Résumé
Metastasis is the second most common type of adrenal gland mass. In patients undergoing follow-up for nonadrenal malignancy, adrenalectomy is performed when metastasis to adrenal gland is suspected on the basis of positron emission tomography-computed tomography (PET-CT) imaging. This study investigated the efficacy of PET-CT in the discrimination of metastatic lesions from nonmetastatic lesions in the adrenal glands. In this multicentric study, data was collected from enrolled centers. Forty-one patients who underwent surgery for suspected adrenal metastases were evaluated retrospectively. The following data types were collected: demographic, primary tumor, maximum standardized uptake value of adrenal mass (a-SUVx) and detectability in computed tomography and/or magnetic resonance imaging, and specimen size and histopathology. Six patients were excluded due to unavailability of PET-CT reports and 4 for being primary adrenal malignancy. The rest were divided into 2 groups (metastatic: n = 17, 55% and nonmetastatic: n = 14, 45%) according to histopathology reports. There was no statistical difference between the analyzed values, except the a-SUVx (P < .05). The a-SUVx cutoff value was defined as 5.50 by receiver operating characteristic curves and compared with literature. There was no statistical difference when each group was divided as low and high (P > .05). It was found that PET-CT was able to discriminate metastatic lesions from primary benign lesions (P = .022). PET-CT can discriminate primary benign lesions and metastatic lesions by cutoff 5.5 value for a-SUVx.
Identifiants
pubmed: 36042684
doi: 10.1097/MD.0000000000030214
pii: 00005792-202208260-00103
pmc: PMC9410641
doi:
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e30214Informations de copyright
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Cingam SR, Karanchi H. Cancer, Metastasis, Adrenal. Treasure Island (FL): StatPearls; 2022.
Miles BJ, Khera M, Schatte EC, et al. Adrenal surgery. 2016. Available at: https://emedicine.medscape.com/article/443536 [access date August 31, 2018].
Romeo V, Maurea S, Guarino S, et al. The role of dynamic post-contrast T1-w MRI sequence to characterize lipid-rich and lipid-poor adrenal adenomas in comparison to non-adenoma lesions: preliminary results. Abdom Radiol (NY). 2018;43:2119–29.
Boland GW, Lee MJ, Gazelle GS, et al. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR Am J Roentgenol. 1998;171:201–4.
Sancho JJ, Triponez F, Montet X, et al. Surgical management of adrenal metastases. Langenbecks Arch Surg. 2012;397:179–94.
Zheng QY, Zhang GH, Zhang Y, et al. Adrenalectomy may increase survival of patients with adrenal metastases. Oncol Lett. 2012;3:917–20.
Quayle FJ, Spitler JA, Pierce RA, et al. Needle biopsy of incidentally discovered adrenal masses is rarely informative and potentially hazardous. Surgery. 2007;142:497–502.
Kim SJ, Lee SW, Pak K, et al. Diagnostic accuracy of (18)F-FDG PET or PET/CT for the characterization of adrenal masses: a systematic review and meta-analysis. Br J Radiol. 2018;91:20170520.
Metser U, Miller E, Lerman H, et al. 18F-FDG PET/CT in the evaluation of adrenal masses. J Nucl Med. 2006;47:32–7.
Han SJ, Kim TS, Jeon SW, et al. Analysis of adrenal masses by 18F-FDG positron emission tomography scanning. Int J Clin Pract. 2007;61:802–9.
Launay N, Silvera S, Tenenbaum F, et al. Value of 18-F-FDG PET/CT and CT in the diagnosis of indeterminate adrenal masses. Int J Endocrinol. 2015;2015:213875.
Pitts A, Ih G, Wei M, et al. Clinical utility of FDG-PET for diagnosis of adrenal mass: a large single-center experience. Hormones (Athens). 2013;12:417–27.
Watanabe H, Kanematsu M, Goshima S, et al. Adrenal-to-liver SUV ratio is the best parameter for differentiation of adrenal metastases from adenomas using 18F-FDG PET/CT. Ann Nucl Med. 2013;27:648–53.
Altinmakas E, Hobbs BP, Ye H, et al. Diagnostic performance of (18-)F-FDG-PET-CT in adrenal lesions using histopathology as reference standard. Abdom Radiol (NY). 2017;42:577–84.